Assessing risks of multiple sclerosis therapies.

Details

Serval ID
serval:BIB_6F31492A65D5
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Assessing risks of multiple sclerosis therapies.
Journal
Journal of the Neurological Sciences
Author(s)
Parfenov V., Schluep M., Du Pasquier R.
ISSN
1878-5883 (Electronic)
ISSN-L
0022-510X
Publication state
Published
Issued date
2013
Peer-reviewed
Oui
Volume
332
Number
1-2
Pages
59-65
Language
english
Notes
Publication types: Journal Article ; pdf : in this review (IK)
Abstract
Over the last two decades, thanks to the discovery of several pharmaceutical agents, multiple sclerosis (MS) has been transformed into a treatable disorder although the degree of therapeutic response may vary considerably. As more medications find their entry into the MS market, a clinician faces a mounting challenge of comparing risk and benefit profiles of various agents in an attempt to find the best treatment approach for each individual patient. In this review, we aim to summarize the available data on safety profiles of available MS therapies while focusing mostly on serious medication specific potential adverse events without discussing the teratogenic potential of each agent (unless there is a black box warning) or hypersensitivity reactions. Our goal is to provide a clinician with guidance on assuring the appropriate safety monitoring for patients treated with one of the agents discussed. We also comment on the future of risk management in MS and discuss possible enhancements to the current model of drug approval process and general strategies to improve the patient safety.
Pubmed
Web of science
Create date
19/08/2013 17:08
Last modification date
20/08/2019 15:28
Usage data